Based on these data, we suggest that anti-galectin-9 treatment results in a better immune control of CLL via suspending the immune suppressive activity of TIM3 on CLL-associated T cells. The gene discussed is LGALS9; the disease is B-cell chronic lymphocytic leukemia.